Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer To Allocate 10 Million Yuan For Community Health In China

This article was originally published in PharmAsia News

Executive Summary

Bayer HealthCare has announced that, starting this month, it will allocate 10 million yuan ($1.45 billion) for China's community health establishment project, the largest ever between a non-government organization and the Ministry of Health. MOH officials say the project will actively publicize community health services in the next three years, including training administrators, developing and extending suitable practice standards, as well as supporting community health organizations to conduct health education and promotion. Besides Bayer, Johnson & Johnson, Pfizer and Novartis have also participated in such exercises. Industry observers point out that the strategy builds up a favorable image of corporate responsibility on social welfare. The perception will help companies concerned project a reliable reputation, benefiting their bids for drug tenders and their drugs' inclusion in the medicine catalog. (Click here for more - Chinese Language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts